Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Cairo University
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07572994CT.gov Evaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain Syndrome | — | Not Yet Recruiting | — | — | — |
NCT07058636CT.gov Efficacy of Adding Greater Occipital Nerve Block to Trigger Point Injection in Patients With Neck Pain | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myofascial Pain Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lidocaine (this asset) | Cairo University | N/A | D · 30 |
| Granisetron | Karolinska Institutet | P4 | BB |
| Imc-1 | Innovative Med Concepts, LLC | P2 | B |
| Capsaicin | Stamford Hospital | P2 | CCC |
| Solvazinc | Cairo University | Early P1 | C |
| Baclofen | Saint Petersburg State University, Russia | Unk | D |
| Prilocaine | Bursa City Hospital | N/A | D |
| Dextrose | Ankara University | Unk | D |
| ha35 | Nakhia Impex LLC | N/A | D |
+3 more in the Myofascial Pain Syndrome cohort
Other indications for Lidocaine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peripheral Neuropathy | — | P4 | BBB · 79 |
| Postherpetic Neuralgia | — | P4 | BBB · 78 |
| Post-Operative Pain, Non-Human Animal | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lidocaine in Myofascial Pain Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lidocaine-myofascial-pain-syndrome-73690
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →